Essential Thrombocythemia Clinical Trial
— BioScoreSMPOfficial title:
Pilot Study for the Development of a Non-invasive Diagnostic Score to Differentiate Between Essential Thrombocythemia, Premyelofibrosis and Myelofibrosis
Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.
Status | Recruiting |
Enrollment | 130 |
Est. completion date | January 30, 2024 |
Est. primary completion date | January 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Adult (18 years of age or older) with the diagnosis of essential thrombocytosis, prefibrotic myelofibrosis or overt myelofibrosis according to WHO 2016 criteria; - Patient who has not received specific treatment for neoplasms; - Patient who has signed the consent to participate in the study; - Patient who has consented to be included in the "Malignant Haemopathies" collection at the University Hospital of Angers or Brest and for whom the samples necessary for the study are available in the biocollection. Exclusion Criteria: - Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis; - Patient with a diagnosis of secondary myelofibrosis; - Pregnant or breastfeeding woman; - Person prived of liberty by judicial or administrative decision; - Person subject to a legal protection measure; |
Country | Name | City | State |
---|---|---|---|
France | Chu Angers | Angers | |
France | CHRU de Brest - Hôpital Morvan | Brest |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | WHO 2016 criteria for prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis | Assessment of the non-invasive diagnostic score against the WHO diagnosis | At the time of diagnosis : disease classification |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04254978 -
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
|
Phase 2 | |
Recruiting |
NCT05482971 -
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
|
Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
Completed |
NCT00666549 -
Research Tissue Bank
|
||
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01192347 -
French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia
|
||
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Recruiting |
NCT04942080 -
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
|
N/A | |
Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Active, not recruiting |
NCT04262141 -
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
|
Phase 2 | |
Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
Active, not recruiting |
NCT00588991 -
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
|
Phase 1 | |
Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
Completed |
NCT01787552 -
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03116542 -
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
|
N/A | |
Recruiting |
NCT06361641 -
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
|
N/A | |
Recruiting |
NCT06378437 -
A Study of GLB-001 in Patients With Myeloid Malignancies
|
Phase 1 | |
Recruiting |
NCT05882773 -
Asian Myeloproliferative Neoplasm (MPN) Registry
|
||
Completed |
NCT02129101 -
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
|
Phase 1 |